Inhibition of puerperal lactation. A double blind study of bromocriptine and placebo.
Bromocriptine and placebo were randomly allocated for three weeks to 52 postpartum patients requiring lactation suppression. Bromocriptine significantly lowered plasma prolactin levels and suppressed breast milk, breast pain and engorgement quicker than placebo. No side-effects were noted and rebound lactation did not occur. Menstruation appeared to re-start sooner when Bromocriptine was given.
D001971:Bromocriptine / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008598:Menstruation; D010146:Pain; D010919:Placebos; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood
D010919:Placebos; D001971:Bromocriptine; D011388:Prolactin